Latest Headlines

41. School Of Science Awarded Over $5.5M To Address Chemistry Challenges In Drug Development 8/31/2023

    Three faculty members at the School of Science at IUPUI — Yongming Deng, Sébastien Laulhé and Ian Webb — will receive grants totaling $5.4M over the next five years from the National Institutes of Health.

42. Optibrium Acquires BioPharmics LLC, Expanding Its 3D Drug Design And Visualisation Offering 8/31/2023

    Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering.

43. Discovery Opens Possibility Of New Ion Channel-Targeting Drugs 8/31/2023

    Ion channels are attractive drug targets due to their importance in health and disease, but finding ways to target a specific ion channel selectively is a major challenge.

44. Asieris Obtained IND Approval From NMPA For APL-1401, A Drug For The Treatment Of Moderately-To-Severely Active Ulcerative Colitis 8/30/2023

    Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Administration (NMPA) has approved the Investigational Drug (IND) application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis (UC).

45. Newly Engineered Bacterial Enzyme Versions Reveal How Antibiotics Could Be More Potent 8/30/2023

    Modern medicine depends on antibiotics to treat infections by disabling targets inside bacterial cells. Once inside these cells, antibiotics bind to certain sites on specific enzyme targets to stop bacterial growth.

46. InxMed Receives Approval To Initiate Phase I Clinical Trial In China For OMTX705, A First-In-Class FAP-Targeting ADC 8/29/2023

    InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approval from China National Medical Products Administration (NMPA) recently.

47. XORTX Submits Orphan Drug Designation Application To The European Medicines Agency (EMA) To Treat Progressive Kidney Disease 8/29/2023

    XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).

48. Faron Receives FDA Orphan Drug Designation For Bexmarilimab In Acute Myeloid Leukemia 8/29/2023

    Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia (AML)

49. Researchers Gain Fascinating New Insights Into Chromosome Shortening – And Identify New Potential Cancer Drug Targets 8/29/2023

    A new study has provided insights into an important biological mechanism that supports survival of aggressive, hard-to-treat cancers – and in the process, uncovered fascinating new information about how cells divide and grow.

50. Lenacapavir: Drug Offers New Hope For Multi-Drug Resistant HIV 8/29/2023

    Onyema Ogbuagu, MD, gets excited about finding new ways to treat HIV—and he is very enthusiastic about lenacapavir, an injection recently approved by the FDA for multi-drug resistant HIV for which he was the principal investigator.